Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension (REHAB-PH)
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Listed as NCT03554291, this PHASE2 trial focuses on Pulmonary Arterial Hypertension and Right Heart Failure and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 10 times since 2019, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2022 — Jun 2023 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jul 2019 — Dec 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Jul 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .